Navigation Links
Need for considering cardiovascular risks before giving HAART for HIV/aids patients

Physicians treating HIV/AIDS patients with highly active antiretroviral treatment (HAART) needs to be careful// of the cardiac risks involved, says researchers from Belgium.

Highly active antiretroviral treatment can dramatically improve the quality of a HIV/AIDS patient’s life expectancy. This is especially helpful for patients with advanced HIV-1 disease. For this patients will have to have a full commitment to the antiviral treatment for life.

However researchers feel in prescribing HAART treatment for these people, physicians should be careful of the recent evidence of increasing cardiovascular and cerebrovascular accidents that are happening with the treatment.

Researchers feel that people infected with HIV have more risk of cardiovascular mortality on taking the HAART treatment than those who haven’t. HAART is associated with risk factors like increased plasma concentrations of triglycerides, total cholesterol, possibly hypertension, insulin resistance etc. HAART treatment can also induce endothelial dysfunction and thereby increase the risk of coronary disease.

Researchers suggest a total assessment of cardiovascular risk factors in patients who are affected with HIV/AIDS before prescribing the highly active antiretroviral treatment. This will make sure that the treatment is given to patients who are most likely to benefit from it.

The research was published in the British Medical Journal.

Reference: British Medical Journal, June 2005

Page: 1

Related medicine news :

1. Britain Reconsidering New Visa Rules for Indian Doctors
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. People who fight wars may be at high risk of cardiovascular disease
4. Low glycemic diet effective for reducing cardiovascular risk
5. Air pollution to affect diabetes patients’ cardiovascular risks
6. Lower risk of cardiovascular disease from tight glucose control
7. Leisure walks with low cardiovascular exercises work best for weight loss
8. Resilin Protein from Flea can be used for cardiovascular disease
9. Unfit teenagers and adults have a higher risk of cardiovascular diseases.
10. Statins reduces cardiovascular risk but no cancer risk.
11. Gene variants hold clues about vulnerability to cardiovascular disease
Post Your Comments:

(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: